Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaki Ri

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Kosuke Saito, et al.
Cancer Science|July 4, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility studyTakahiko Yasuda, Masashi Sanada, Dai Nishijima, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
Blood Neoplasia|June 23, 2025
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myelomaTomoyasu Jo, Kyoko Yoshihara, Masaki Ri, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Kosuke Saito, et al.
Cancer Science|July 4, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility studyTakahiko Yasuda, Masashi Sanada, Dai Nishijima, et al.
Pageof 12